In persons with stage III melanoma, frailty—not age—was associated with decreased disease-free survival and distant disease-free survival, and with more surgical complications.
Shave biopsies may potentially hamper accurate diagnosis and staging of melanoma, but a study indicates that they are reasonably safe and accurate for the initial evaluation of the disease.
A tumor-suppressing protein called alpha-catenin appears to stop the development of squamous cell carcinoma by keeping another protein—the cancer-causing Yap1—in check.
The identification of several plasma biomarkers that appear to predict the risk of metastasis in melanoma could lead to more convenient and less costly monitoring of persons with this cancer.
Overall, cancer incidence rates fell approximately 1% annually and overall death rates decreased by an average of 1.6% annually between 2003 and 2007.
Celecoxib (Celebrex) may ward off squamous and basal cell carcinomas in persons with extensive actinic damage who are at high risk for developing nonmelanoma skin cancers.